Innovative Therapies | Transforming Lives

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

New data on Kineta’s small molecule RIG-I agonists in tumor models to be unveiled

SEATTLE, WA, March 22, 2018 – Kineta Immuno-oncology, LLC, a biotechnology company focused on developing disruptive technologies to turn cold tumors hot, today announced that they have been invited to present at the Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations. Dr. Peter Probst, Kineta Immuno-oncology Head of Immunology, will present a poster on Kineta’s RIG-I Immuno-oncology program. The conference takes place on March 23-27 at the Fairmont, The Queen Elizabeth Hotel in Montreal, Canada.

Dr. Probst will present new data on Kineta Immuno-oncology’s RIG-I agonists demonstrating significant reduction in tumor growth in two mouse tumor models; CT26 colon carcinoma and B16F10 melanoma. Additionally, a newly identified RIG-I lead candidate with potent innate immune activation and immunogenic cell death activities showing orthogonal confirmation around the lead series will be shown.

Dr. Probst will be presenting scientific poster #3016 entitled “Small molecule RIG-I agonists induce innate immune responses, immogenic tumor cell death and in vivo protective immune responses in a colon carcinoma model” on March 26th between 7:30-10pm.


Kineta, Inc. is an emerging biotech company that fills a void in the biopharmaceutical industry by efficiently advancing first in class immuno-therapies from discovery to proof of concept.  Kineta is developing a focused pipeline of novel therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research. For more information on Kineta, Inc. visit our website, www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.